266 related articles for article (PubMed ID: 23867503)
21. FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma.
Shi Y; Liu X; Fredimoses M; Song M; Chen H; Liu K; Lee MH; Dong Z
J Cell Biochem; 2018 Feb; 119(2):2231-2239. PubMed ID: 28857247
[TBL] [Abstract][Full Text] [Related]
22. p63 expression in normal skin and usual cutaneous carcinomas.
Reis-Filho JS; Torio B; Albergaria A; Schmitt FC
J Cutan Pathol; 2002 Oct; 29(9):517-23. PubMed ID: 12358808
[TBL] [Abstract][Full Text] [Related]
23. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.
Hsieh MH; Choe JH; Gadhvi J; Kim YJ; Arguez MA; Palmer M; Gerold H; Nowak C; Do H; Mazambani S; Knighton JK; Cha M; Goodwin J; Kang MK; Jeong JY; Lee SY; Faubert B; Xuan Z; Abel ED; Scafoglio C; Shackelford DB; Minna JD; Singh PK; Shulaev V; Bleris L; Hoyt K; Kim J; Inoue M; DeBerardinis RJ; Kim TH; Kim JW
Cell Rep; 2019 Aug; 28(7):1860-1878.e9. PubMed ID: 31412252
[TBL] [Abstract][Full Text] [Related]
24. Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
Kas SM; de Ruiter JR; Schipper K; Schut E; Bombardelli L; Wientjens E; Drenth AP; de Korte-Grimmerink R; Mahakena S; Phillips C; Smith PD; Klarenbeek S; van de Wetering K; Berns A; Wessels LFA; Jonkers J
Cancer Res; 2018 Oct; 78(19):5668-5679. PubMed ID: 30115694
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
26. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
27. Expression profiles of p63, p53, survivin, and hTERT in skin tumors.
Park HR; Min SK; Cho HD; Kim KH; Shin HS; Park YE
J Cutan Pathol; 2004 Sep; 31(8):544-9. PubMed ID: 15268709
[TBL] [Abstract][Full Text] [Related]
28. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
29. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
Maehara O; Suda G; Natsuizaka M; Ohnishi S; Komatsu Y; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Shimazaki T; Kimura M; Asano A; Fujimoto Y; Ohashi S; Kagawa S; Kinugasa H; Naganuma S; Whelan KA; Nakagawa H; Nakagawa K; Takeda H; Sakamoto N
Carcinogenesis; 2017 Oct; 38(11):1073-1083. PubMed ID: 28927233
[TBL] [Abstract][Full Text] [Related]
31. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
32. Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma.
Herfs M; Hubert P; Suarez-Carmona M; Reschner A; Saussez S; Berx G; Savagner P; Boniver J; Delvenne P
Am J Pathol; 2010 Apr; 176(4):1941-9. PubMed ID: 20150431
[TBL] [Abstract][Full Text] [Related]
33. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
34. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
Sakiz D; Turkmenoglu TT; Kabukcuoglu F
Pathol Res Pract; 2009; 205(9):589-94. PubMed ID: 19577853
[TBL] [Abstract][Full Text] [Related]
35. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
36. ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
Saladi SV; Ross K; Karaayvaz M; Tata PR; Mou H; Rajagopal J; Ramaswamy S; Ellisen LW
Cancer Cell; 2017 Jan; 31(1):35-49. PubMed ID: 28041841
[TBL] [Abstract][Full Text] [Related]
37. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
38. Molecular Mechanisms of p63-Mediated Squamous Cancer Pathogenesis.
Moses MA; George AL; Sakakibara N; Mahmood K; Ponnamperuma RM; King KE; Weinberg WC
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340447
[TBL] [Abstract][Full Text] [Related]
39. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
40. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
